Saladax Secures $9M Loan Facility from GE Capital

Jun 21, 2011

NEW YORK (GenomeWeb News) – Saladax Biomedical today announced the completion of a $9 million debt financing with GE Capital.

The secured loan facility will be used to support commercialization of Saladax's My5-FU assay, which measures levels of 5-flourouracil, a chemotherapy used in conjunction with other therapies for colorectal cancer and other solid tumors. The test is currently available in the European Union and Australia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Genome Research

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

To the Brink

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Just Like Your Old Pop

Researchers report that paternally inherited genes are more likely to be expressed in mice.

This Week in PNAS

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

Featured White Papers

Reducing the variability of pre-analytical handling of biological samples

Main menu